Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 1;10(1):364.
doi: 10.1186/s13104-017-2696-4.

The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus

Affiliations

The in vitro effects of interferon-gamma, alone or in combination with amphotericin B, tested against the pathogenic fungi Candida albicans and Aspergillus fumigatus

Moufid El-Khoury et al. BMC Res Notes. .

Abstract

Objective: Recent studies into the antifungal activity of NK-cells against the Aspergillus fumigatus have presented differing accounts on their mode of antifungal activity. One of these mechanisms proposed that NK-cells may kill the fungus via the direct effects of exposure to Interferon gamma (IFN-γ).

Results: In this study we investigated the direct antifungal effects of recombinant human IFN-γ against a range of pathogenic fungi by measuring cellular damage using an XTT-based assay and cell viability through plate counts. It was found that 32 pg/ml of IFN-γ exhibited a significant but small antifungal effect on A. fumigatus (p = 0.02), Aspergillus flavus (p = 0.04) and Saccharomyces cerevisiae (p = 0.03), inhibiting growth by 6, 11 and 17% respectively. No significant inhibitory effects were observed in Candida species (p > 0.05 for all species tested) or Cryptococus neoformans (p = 0.98). Short term exposure (3 h) to a combination of amphotericin B (1 µg/ml) and IFN-γ (32 pg/ml) increased the effectiveness of amphotericin B against A. fumigatus and S. cerevisiae but not Candida albicans. These data suggest that IFN-γ does not possess strong antifungal activity but can enhance the effect of amphotericin B under some testing conditions against Aspergillus species.

Keywords: Amphotericin B; Antifungals; Aspergillosis; Interferon-gamma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A Measurement of inhibition caused by treatment with IFN-γ on several pathogenic fungi using the XTT assay. The results were expressed as the percentage of the metabolic activity of treated cells compared to untreated cells. The absorbance reading at OD492 for the untreated control for each species was taken as 100%; the mean OD492 value was 0.44 (±0.07). The data shown are means and standard errors of the growth inhibition (treated/untreated control) from three replicate experiments. Data were analysed by t-test to compare low to high doses of IFN-γ (*p < 0.05, **p < 0.01, ***p < 0.001), p-values for each test are shown in the figure. B Measurement of inhibition caused by incubation of several pathogenic fungi with IFN-γ using the XTT assay over an extended dose range. No significant differences in fungal survival were found when treatment with 32 pg/ml to treatment with 50 or 100 pg/ml of IFN-γ were compared. Data in 1B were analysed by one-way ANOVA (p-value shown in the figure) and Dunn’s post-test (p-values shown as asterisks) to compare the range of doses of IFN-γ (*p < 0.05, **p < 0.01, ***p < 0.001). Asterisks indicate that doses are significantly different to the lowest dose
Fig. 2
Fig. 2
The effect of short term exposure to IFN-γ alone or in combination with amphotericin B on selected fungi. The addition of (I+; 32 pg/ml) and amphotericin B (A+; 1.0 µg/ml. A++; 2.0 µg/ml) were tested on C. albicans, S. cerevisiae and A. fumigatus. The effect was measured as CFU following a three hour incubation relative to the untreated control samples (100%) were used to calculate the growth inhibition a S. cerevisiae 3.1 × 104/ml (p < 0.0001); b C. albicans 3.5 × 104/ml (p = 0.0011) and c A. fumigatus 4.1 × 104/ml (p = 0.002). The data presented are means and standard errors of growth inhibition (treated/untreated) from, three replicate experiments. The data was analysed by one-way ANOVA and Dunn’s multiple comparison test to compare all treatments (*p < 0.05, **p < 0.01, ***p < 0.001). Three independent experiments were conducted for each treatment

References

    1. Calton EA, Le Doare K, Appleby G, Chisholm JC, Sharland M, Ladhani SN, Participants C. Invasive bacterial and fungal infections in paediatric patients with cancer: incidence, risk factors, aetiology and outcomes in a UK regional cohort 2009–2011. Pediatr Blood Cancer. 2014;61(7):1239–1245. doi: 10.1002/pbc.24995. - DOI - PubMed
    1. Munoz P, Ceron I, Valerio M, Palomo J, Villa A, Eworo A, Fernandez-Yanez J, Guinea J, Bouza E. Invasive aspergillosis among heart transplant recipients: a 24-year perspective. J Heart Lung Transplant Off Publ Int Soc Heart Transplant. 2014;33(3):278–288. doi: 10.1016/j.healun.2013.11.003. - DOI - PubMed
    1. Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis. 2013;26(6):493–500. doi: 10.1097/QCO.0000000000000005. - DOI - PubMed
    1. Armstrong-James D, Harrison TS. Immunotherapy for fungal infections. Curr Opin Microbiol. 2012;15(4):434–439. doi: 10.1016/j.mib.2012.06.001. - DOI - PubMed
    1. Park SJ, Hughes MA, Burdick M, Strieter RM, Mehrad B. Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis. J Immunol. 2009;182(7):4306–4312. doi: 10.4049/jimmunol.0803462. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources